Open AccessSequencing or not sequencing multikinase inhibitors in kidney cancer: this is the dilemma
Author(s) -
Chiara Paglino,
Camillo Porta
Publication year - 2011
Publication title -
oncology reviews
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.637
H-Index - 21
eISSN - 1970-5565
pISSN - 1970-5557
DOI - 10.4081/oncol.2010.42
Subject(s) - temsirolimus , medicine , sunitinib , pazopanib , sorafenib , everolimus , bevacizumab , kidney cancer , oncology , renal cell carcinoma , clinical trial , pharmacology , discovery and development of mtor inhibitors , hepatocellular carcinoma , pi3k/akt/mtor pathway , chemotherapy , apoptosis , biochemistry , chemistry
With the recent development of targeted therapies (Sorafenib, Sunitinib, Temsirolimus, Bevacizumab plus Interferon-a, Everolimus and now also Pazopanib) patients with advanced renal cell carcinoma (RCC) now have a wide range of treatment options, all of which have shown both relevant clinical activity and manageable safety profile. This abundance of active treatments, coupled with relatively limited information, we have gathered from registrative phase III trials have raised the question of how to use these agents optimally...